– Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare company Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on therapeutic solutions improving the care of patients undergoing significant treatments such as surgery, other invasive…
– Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif. — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market…
– First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced…
– Irvine, CA (United States) – Gilde Healthcare portfolio company Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder…
– Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma Group plc (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company…
– Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support…
– Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, has announced that it has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The…
– Utrecht (the Netherlands) and Philadelphia (United States) – Gilde Healthcare company Lava Therapeutics (“LAVA”) announced that James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation,…
– Utrecht (the Netherlands) – Gilde Healthcare today announced it has sold its majority stake in occupational health provider BlijWerkt to Mentha Capital, subject to approval by the Dutch Healthcare Authority. Led by Gilde, BlijWerkt has become a national player and challenger to the…
– Utrecht (the Netherlands) and London, (UK) – Lumeon, the leader in Care Pathway Management (CPM), today announced that it has entered a strategic partnership with Medtronic, a global leader in medical technology, services, and solutions, that will support Medtronic’s European healthcare…
– Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today…
– Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced…
– Utrecht (The Netherlands), Palma (Spain) and San Diego (US) – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage…
– Utrecht (The Netherlands) and Mont-Saint-Guibert (Belgium) – Nyxoah S.A., a healthtech company focused on the development of innovative solutions and services for sleep related disorders, announced today the publication of data from the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation…
– Durable Outcomes Highlighted in Plenary Session Presentation; Expanding on Positive Topline Data Released in August More than 350 Physicians Attended a Symposium Highlighting Hands-on Physician Experience with the Recently FDA-Approved Axonics r-SNM® System1 IRVINE, Calif.— Axonics…
– Utrecht (The Netherlands) and Cambridge (Massachusetts) – Gilde Healthcare company Acacia Pharma (BRU:ACPH), a pharmaceutical company developing and commercializing hospital products for US and international markets, announces that the US Food and Drug Administration (FDA) has accepted…
– Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company Axonics, a medical technology company that commercializes a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced the…
– Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif. and PARIS – Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market…
– Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company CVRx, Inc., announces today that it received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States.…
– Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial…
– Veteran Leader Brings Extensive Experience from Both Pharma and Device Industries San Jose, Calif., US - Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and…
– Cambridge, UK and Indianapolis, US - Acacia Pharma, a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official Type A meeting minutes from the US Food and Drug Administration (“FDA”) relating to the…
– IRVINE, Calif., /PRNewswire/ -- Inari Medical, Inc. announced today that the company has appointed Thomas M. Tu, M.D. as Chief Medical Officer. Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was the lead author in the publication of the…
– Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis Round led by Spanish investor Caixa Capital Risc Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to…